30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q14 Revenue: K2M

$47.6MM, +20% (U.S. $34.4MM, +25%; ex-U.S. $13.2MM, +6%)

  • U.S. Complex Spine $14.6MM, +29%
  • U.S. Minimally Invasive $5.2MM, +6%
  • U.S. Degenerative $14.5MM, +30%


  • Same-store, same-product price decline in low- to mid-single-digits
  • Taking share in the U.S., not relying solely on ex-U.S. to drive overall growth
  • Ex-U.S., strongest sales in Scandinavia, Australia and certain direct markets (Germany and U.K.)
  • U.S. Complex Spine driven by surgeon conversion and higher procedure volumes lasting deeper into the summer
  • Surgeon conversions may be supported by focus on high-profile academic centers
  • Received FDA 510(k) clearance and CE Mark approval for MESA Hooks
  • Launched EVEREST Minimally Invasive Spinal System and CASPIAN Occipital Anchor
  • Claims meaningful presence in ~50% of U.S. NFL cities; added sales reps in new ones during 3Q
  • Added ~100 direct U.S. sales reps in past 2 years (plus a number of agent partners)